| アブストラクト | The role of glucagon-like peptide-1 receptor agonists (GLP-1 RA) and dipeptidyl peptidase-4 inhibitors (DPP-4i) in mitigating the risk of atrial fibrillation (AF) remains unknown. We interrogated the Food and Drug Administration's Adverse Event Reporting System (FAERS) database to study the association between AF-related adverse events and the use of GLP-1 RA and DPP-4i. A signal of disproportionate reporting of AF was detected with the DPP-4i group compared with all the other drugs in the FAERS database [ROR, 2.56; 95% confidence interval (CI), 2.10-3.12], whereas there was no disproportionality signal detected with the GLP-1 RA group (ROR, 0.90; 95% CI, 0.78-1.03) although liraglutide showed a significant disproportionality signal (ROR, 2.51; 95% CI, 2.00-3.15). Our analysis supports the existing body of literature demonstrating the cardiac safety of GLP-1 RA but raises concerns about the apparent increase in the risk of AF associated with DPP-4i. Further clinical and translational studies are needed to validate these findings. |
|---|
| ジャーナル名 | Cardiovascular endocrinology & metabolism |
|---|
| Pubmed追加日 | 2022/6/16 |
|---|
| 投稿者 | Thotamgari, Sahith Reddy; Grewal, Udhayvir Singh; Sheth, Aakash R; Babbili, Akhilesh; Dominic, Paari |
|---|
| 組織名 | Department of Medicine, Louisiana State University Health Sciences;Center-Shreveport.;Center of Excellence for Cardiovascular Diseases & Sciences, Louisiana State;University Health Sciences Center-Shreveport, Shreveport, Louisiana, USA. |
|---|
| Pubmed リンク | https://www.ncbi.nlm.nih.gov/pubmed/35702660/ |
|---|
